173 related articles for article (PubMed ID: 37146241)
21. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
Hsu HJ; Tung CP; Yu CM; Chen CY; Chen HS; Huang YC; Tsai PH; Lin SI; Peng HP; Chiu YK; Tsou YL; Kuo WY; Jian JW; Hung FH; Hsieh CY; Hsiao M; Chuang SS; Shen CN; Wang YA; Yang AS
Sci Rep; 2021 Jul; 11(1):15430. PubMed ID: 34326410
[TBL] [Abstract][Full Text] [Related]
22. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
23. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.
Wang B; Kuroiwa JM; He LZ; Charalambous A; Keler T; Steinman RM
Ann N Y Acad Sci; 2009 Sep; 1174():6-17. PubMed ID: 19769731
[TBL] [Abstract][Full Text] [Related]
24. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P
J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106
[TBL] [Abstract][Full Text] [Related]
25. Mesothelin-targeted CAR-T cell therapy for solid tumors.
Klampatsa A; Dimou V; Albelda SM
Expert Opin Biol Ther; 2021 Apr; 21(4):473-486. PubMed ID: 33176519
[No Abstract] [Full Text] [Related]
26. Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors.
Ding J; Guyette S; Schrand B; Geirut J; Horton H; Guo G; Delgoffe G; Menk A; Baeuerle PA; Hofmeister R; Tighe R
Oncoimmunology; 2023; 12(1):2182058. PubMed ID: 36875551
[TBL] [Abstract][Full Text] [Related]
27. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
[TBL] [Abstract][Full Text] [Related]
28. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
Front Immunol; 2021; 12():628906. PubMed ID: 33777013
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
[TBL] [Abstract][Full Text] [Related]
30. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models.
Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD
J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622
[TBL] [Abstract][Full Text] [Related]
31. Construction of a
Hou X; Wang F; Meng X; Li D; Ding J; Chen Y; Wang Z; Zhu H; Yang Z
Mol Pharm; 2022 Oct; 19(10):3623-3631. PubMed ID: 35904514
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors.
Molloy ME; Austin RJ; Lemon BD; Aaron WH; Ganti V; Jones A; Jones SD; Strobel KL; Patnaik P; Sexton K; Tatalick L; Yu TZ; Baeuerle PA; Law CL; Wesche H
Clin Cancer Res; 2021 Mar; 27(5):1452-1462. PubMed ID: 33262134
[TBL] [Abstract][Full Text] [Related]
33. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.
Chu GJ; Linton A; Kao S; Klebe S; Adelstein S; Yeo D; Rasko JEJ; Cooper WA
Histopathology; 2023 Aug; 83(2):202-210. PubMed ID: 37040900
[TBL] [Abstract][Full Text] [Related]
34. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer.
Cao B; Liu M; Huang J; Zhou J; Li J; Lian H; Huang W; Guo Y; Yang S; Lin L; Cai M; Zhi C; Wu J; Liang L; Hu Y; Hu H; He J; Liang B; Zhao Q; Zhu K
Int J Biol Sci; 2021; 17(14):3850-3861. PubMed ID: 34671203
[No Abstract] [Full Text] [Related]
35. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J
Front Immunol; 2024; 15():1362904. PubMed ID: 38855110
[TBL] [Abstract][Full Text] [Related]
36. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.
Zhang Z; Jiang D; Yang H; He Z; Liu X; Qin W; Li L; Wang C; Li Y; Li H; Xu H; Jin H; Qian Q
Cell Death Dis; 2019 Jun; 10(7):476. PubMed ID: 31209210
[TBL] [Abstract][Full Text] [Related]
37. Fully human antibody V
Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386
[TBL] [Abstract][Full Text] [Related]
38. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy targeting mesothelin in acute myeloid leukemia.
Wang Q; Gong R
J Leukoc Biol; 2022 Oct; 112(4):813-821. PubMed ID: 35946307
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
